NCT05906953View on ClinicalTrials.gov

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Leber Congenital AmaurosisInherited Retinal Diseases Caused by RPE65 Mutations
Interventions
DRUG

HG004

Low dose Medium dose High dose

Trial Locations (3)

77707

RECRUITING

Research Site, Houston

95817

RECRUITING

Research Site, Sacramento

Unknown

RECRUITING

Research Site, Shanghai

Sponsors
All Listed Sponsors
lead

HuidaGene Therapeutics Co., Ltd.

INDUSTRY